EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Similar Efficacy and Safety of Mizoribine Versus Cyclophosphamide in Patients With Steroid‐Resistant Nephrotic Syndrome: A Multicenter Randomized Non‐Inferiority Trial

Zheyi Dong, Zhonggao Xu, Lihua Wang, Zhaohui Ni, Hongguang Zheng, Xueqing Yu, Yan Xu, Aiping Yin, Yani He, Ping Luo, Xinzhou Zhang, Hongli Lin und 15 weitere

MedComm · 2026-12 · 7 (12)

DOI: 10.1002/mco2.71156 ↗

Kurz gefasst

Fachartikel in der Zeitschrift MedComm, online erschienen am 20.11.2026. Verfasst von Zheyi Dong und 26 weiteren Autor:innen. Die Arbeit nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Asahi Kasei Therapeutics Corporation.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Effective immunosuppression is necessary for steroid‐resistant nephrotic syndrome (SRPNS) treatment, but intravenous cyclophosphamide (CY) may impose treatment‐related burdens. In this multicenter, open‐label, randomized non‐inferiority trial, the efficacy and safety of oral mizoribine (MZR) was evaluated among SRPNS patients in China and compared with those of intravenous CY. A total of 239 patients with persistent proteinuria despite adequate steroid therapy were randomized 1:1 to receive MZR or CY in combination with standardized steroid‐tapering therapy. The primary endpoint was the total remission (TR) rate, defined as complete or partial remission, at Week 52. The TR rates were 50.9% and 51.9% in the MZR and CY groups, respectively. Statistical analysis returned a relative risk ratio of 0.981 (95% confidence interval: 0.756–1.274), with a lower confidence limit exceeding the prespecified non‐inferiority margin of 0.674, demonstrating the non‐inferiority of MZR to CY. Treatment‐emergent adverse events occurred in 84.3% and 85.0% of patients in the MZR and CY groups, respectively. Oral MZR demonstrated non‐inferior efficacy and a safety profile comparable to intravenous CY. These findings support MZR as a practical therapeutic alternative that may expand treatment options for Chinese patients with SRPNS, particularly those requiring long‐term disease management and ongoing immunosuppression. Trial Registration : ClinicalTrials.gov Identifier: NCT02257697 https://clinicaltrials.gov/study/NCT02257697?term=NCT02257697&rank=1 .

Förderung

  • Asahi Kasei Therapeutics Corporation

Zitieren

APA

Dong, Z., Xu, Z., Wang, L., Ni, Z., Zheng, H., Yu, X., Xu, Y., Yin, A., He, Y., Luo, P., Zhang, X., Lin, H., Li, Y., Xu, G., Liang, X., Jiang, G., Wang, R., Li, W., Wan, J., …, & Chen, X. (2026). Similar Efficacy and Safety of Mizoribine Versus Cyclophosphamide in Patients With Steroid‐Resistant Nephrotic Syndrome: A Multicenter Randomized Non‐Inferiority Trial. MedComm, 7(12). https://doi.org/10.1002/mco2.71156

Vancouver

Dong Z, Xu Z, Wang L, Ni Z, Zheng H, Yu X, et al. Similar Efficacy and Safety of Mizoribine Versus Cyclophosphamide in Patients With Steroid‐Resistant Nephrotic Syndrome: A Multicenter Randomized Non‐Inferiority Trial. MedComm. 2026;7(12). doi:10.1002/mco2.71156

BibTeX
@article{Dong2026,
  author = {Dong, Zheyi and Xu, Zhonggao and Wang, Lihua and Ni, Zhaohui and Zheng, Hongguang and Yu, Xueqing and Xu, Yan and Yin, Aiping and He, Yani and Luo, Ping and Zhang, Xinzhou and Lin, Hongli and Li, Ying and Xu, Gang and Liang, Xinling and Jiang, Gengru and Wang, Rong and Li, Wenge and Wan, Jianxin and Liu, Wenhu and Shi, Shumei and Yu, Yueming and Wang, Hua and Yamaguchi, Seika and Cai, Guang‐yan and Zhang, Li and Chen, Xiangmei},
  title = {Similar Efficacy and Safety of Mizoribine Versus Cyclophosphamide in Patients With Steroid‐Resistant Nephrotic Syndrome: A Multicenter Randomized Non‐Inferiority Trial},
  journal = {MedComm},
  year = {2026},
  volume = {7},
  number = {12},
  doi = {10.1002/mco2.71156}
}
Kostenlos starten →